Comparison of Long-Acting G-CSF (PD-Lasta) with Short-Acting G-CSF (PD-Grastim) in Neutrophil Recovery Following Consolidation Chemotherapy with High-Dose Cytarabine in Acute Myeloid Leukemia: A Randomized Clinical Trial

Background: acute myeloid leukemia (aml) patients are often neutropenic as a result of their disease alone or following their chemotherapy. in this randomized clinical trial the efficacy of iranian short-acting (pd-grastim) and long-acting g-csf (pd-lasta) were compared in term of time to recovery from neutropenia in de novo aml patients following the consolidation chemotherapy. materials and methods: patients (n = 51) received one or two courses of cytarabine and daunorubicin as an induction. if complete remission was achieved, the treatment was followed by high-dose cytarabine as consolidation chemotherapy. twenty four hours after the consolidation chemotherapy, patient were randomized to receive either daily short-acting g-csf (pd-grastim) (300 μg/kg) or single-dose long-acting g-csf (pd-lasta) (6 mg). results: the median time to recovery of neutrophils was 11.00 and 13.00 days for short-acting g-csf (pd-grastim) (n=22) and long-acting g-csf (pd-lasta) (n=29) groups, respectively (u=186.5, p>0.05 two-tailed). incidence of adverse effects was similar in both short-acting g-csf (pd-grastim) and long-acting g-csf (pd-lasta) groups. conclusion: overall, data show that iranian long-acting g-csf (pd-lasta) was not significantly different with iranian short-acting g-csf (pd-grastim).